Lian et al. (2019) thought that the number of tumors and pathological stage were closely related to recurrence. Besides, previous studies had proved that drugs are concerned with recurrence, which contribute to high heterogeneity (Malmstrom et al., 2009; Yang et al., 2017). By the way, Chiancone et al recently reported that systemic inflammatory markers were significantly associated with bladder cancer recurrence or progression, including C-reactive protein, erythrocyte sedimentation rate and neutrophil-to-lymphocyte ratio (Chiancone et al., 2021). The gene discussed is CRP; the disease is urinary bladder carcinoma.